MA30394B1 - Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p - Google Patents

Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p

Info

Publication number
MA30394B1
MA30394B1 MA31347A MA31347A MA30394B1 MA 30394 B1 MA30394 B1 MA 30394B1 MA 31347 A MA31347 A MA 31347A MA 31347 A MA31347 A MA 31347A MA 30394 B1 MA30394 B1 MA 30394B1
Authority
MA
Morocco
Prior art keywords
synthesis
substance
acylaminoalcenylene
agonists
amides
Prior art date
Application number
MA31347A
Other languages
English (en)
French (fr)
Inventor
Robert Portmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0607532A external-priority patent/GB0607532D0/en
Priority claimed from GB0610244A external-priority patent/GB0610244D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30394B1 publication Critical patent/MA30394B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA31347A 2006-04-13 2008-11-03 Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p MA30394B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0607532A GB0607532D0 (en) 2006-04-13 2006-04-13 Organic compounds
GB0610244A GB0610244D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
MA30394B1 true MA30394B1 (fr) 2009-05-04

Family

ID=38324102

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31347A MA30394B1 (fr) 2006-04-13 2008-11-03 Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p

Country Status (28)

Country Link
US (2) US8008479B2 (enExample)
EP (1) EP2010498B1 (enExample)
JP (1) JP5208917B2 (enExample)
KR (1) KR20080108291A (enExample)
AR (1) AR060506A1 (enExample)
AT (1) ATE486853T1 (enExample)
AU (1) AU2007237482B2 (enExample)
CA (1) CA2645362C (enExample)
CL (1) CL2007001040A1 (enExample)
CY (1) CY1111294T1 (enExample)
DE (1) DE602007010269D1 (enExample)
DK (1) DK2010498T3 (enExample)
EC (1) ECSP088820A (enExample)
GT (1) GT200800209A (enExample)
HR (1) HRP20110045T1 (enExample)
JO (1) JO2630B1 (enExample)
MA (1) MA30394B1 (enExample)
MX (1) MX2008013117A (enExample)
MY (1) MY145069A (enExample)
NO (1) NO20084783L (enExample)
NZ (1) NZ571142A (enExample)
PE (1) PE20071223A1 (enExample)
PL (1) PL2010498T3 (enExample)
PT (1) PT2010498E (enExample)
RU (1) RU2433122C2 (enExample)
SI (1) SI2010498T1 (enExample)
TW (1) TW200815358A (enExample)
WO (1) WO2007118651A1 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790699B2 (en) 2004-10-12 2010-09-07 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8013007B2 (en) 2007-02-26 2011-09-06 Concert Pharmaceuticals, Inc. Alpha 1A-adrenoceptor antagonists
WO2008109175A1 (en) 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
CA2681628C (en) 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US8349817B2 (en) 2007-04-25 2013-01-08 Concert Pharmaceuticals, Inc. Analogues of cilostazol
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
MX370608B (es) 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
WO2008141021A1 (en) 2007-05-08 2008-11-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
MX2009013565A (es) 2007-06-12 2010-06-02 Concert Pharmaceuticals Inc Derivados de azapeptidos.
US7687509B2 (en) 2007-07-09 2010-03-30 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives
JP5389028B2 (ja) 2007-08-14 2014-01-15 コンサート ファーマシューティカルズ インコーポレイテッド 置換オキサゾリジノン誘導体
JP2010537717A (ja) 2007-08-28 2010-12-09 エフ エム シー コーポレーション 遅効性自己ゲル化アルギネートシステムおよびその用途
MX2010002679A (es) 2007-09-12 2010-03-29 Concert Pharmaceuticals Inc Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8084464B2 (en) 2007-12-18 2011-12-27 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
US8609673B2 (en) 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
US7855204B2 (en) 2008-01-22 2010-12-21 Concert Pharmaceuticals Inc. Derivatives of gefitinib
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
WO2009128947A1 (en) 2008-04-17 2009-10-22 Concert Pharmaceuticals, Inc. Piperazine derivatives
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
HRP20140195T1 (hr) 2008-08-29 2014-04-11 Concert Pharmaceuticals Inc. Supstituirani derivati triazolopiridazina
EP2334621A1 (en) 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
JP5730769B2 (ja) 2008-09-19 2015-06-10 コンサート ファーマシューティカルズ インコーポレイテッド モルヒナン化合物
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2400953A1 (en) * 2009-02-24 2012-01-04 Novartis AG Uses of nk receptor antagonists
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
DE102009001446A1 (de) 2009-03-10 2010-09-23 Evonik Rohmax Additives Gmbh Verwendung von Kammpolymeren als Antifatigue-Additive
WO2010107791A2 (en) 2009-03-17 2010-09-23 Concert Pharmaceuticals, Inc. Pyrazinoisoquinoline compounds
WO2010108103A1 (en) * 2009-03-19 2010-09-23 Concert Pharmaceuticals, Inc. Azepan-2-one derivatives
CA2759251C (en) 2009-04-23 2017-01-03 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
WO2010135579A1 (en) 2009-05-22 2010-11-25 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
CA2765015C (en) 2009-06-18 2020-05-05 Concert Pharmaceuticals, Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US8557815B2 (en) 2009-08-14 2013-10-15 Concert Pharmaceuticals, Inc. Substituted triazolophthalazine derivatives
CA2771331A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011063001A1 (en) 2009-11-18 2011-05-26 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
DE102010001040A1 (de) 2010-01-20 2011-07-21 Evonik RohMax Additives GmbH, 64293 (Meth)acrylat-Polymere zur Verbesserung des Viskositätsindexes
EP3144296A1 (en) 2010-03-02 2017-03-22 Concert Pharmaceuticals, Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US9226801B2 (en) * 2010-03-08 2016-01-05 Ibur, Llc Custom linkable imaging and multifunctional tray
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031072A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2012122028A2 (en) 2011-03-04 2012-09-13 Concert Pharmaceuticals Inc. Pyrazinoisoquinoline compounds
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
WO2014008417A1 (en) 2012-07-04 2014-01-09 Concert Pharmaceuticals, Inc. Deuterated vercirnon
CA2908929C (en) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Deuterated idebenone
CA2879400A1 (en) 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
EP2922838B1 (en) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
MX2015008829A (es) 2013-01-09 2016-04-25 Concert Pharmaceuticals Inc Momelotinib deuterado.
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
HK1258473A1 (zh) 2015-09-25 2019-11-15 Vertex Pharmaceuticals (Europe) Limited 氘代cftr增效剂
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
WO2019109021A1 (en) 2017-12-01 2019-06-06 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2020206367A1 (en) 2019-04-03 2020-10-08 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69602087T2 (de) 1995-02-22 1999-09-09 Novartis Ag 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB0010958D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20080108291A (ko) 2008-12-12
HK1125640A1 (en) 2009-08-14
ECSP088820A (es) 2008-11-27
DE602007010269D1 (de) 2010-12-16
WO2007118651A1 (en) 2007-10-25
US20110282053A1 (en) 2011-11-17
CA2645362A1 (en) 2007-10-25
US20090137797A1 (en) 2009-05-28
RU2008145102A (ru) 2010-05-27
PT2010498E (pt) 2011-02-08
GT200800209A (es) 2008-12-15
CL2007001040A1 (es) 2008-03-14
AR060506A1 (es) 2008-06-25
PL2010498T3 (pl) 2011-04-29
CY1111294T1 (el) 2015-08-05
JP2009533369A (ja) 2009-09-17
JP5208917B2 (ja) 2013-06-12
RU2433122C2 (ru) 2011-11-10
EP2010498A1 (en) 2009-01-07
DK2010498T3 (da) 2011-02-14
NO20084783L (no) 2008-11-12
CA2645362C (en) 2013-07-16
AU2007237482A1 (en) 2007-10-25
ATE486853T1 (de) 2010-11-15
TW200815358A (en) 2008-04-01
US8008479B2 (en) 2011-08-30
HRP20110045T1 (hr) 2011-02-28
JO2630B1 (en) 2012-06-17
PE20071223A1 (es) 2008-01-22
NZ571142A (en) 2011-02-25
AU2007237482B2 (en) 2011-03-17
MX2008013117A (es) 2008-10-21
MY145069A (en) 2011-12-15
SI2010498T1 (sl) 2011-03-31
EP2010498B1 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA31373B1 (fr) Composes amino-heterocycliques
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine
EP1841426A4 (en) ACTIVE TERTIARY CARBINAMINES WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER DISEASE AS INHIBITORS OF BETA-SECRETASE
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
MA31763B1 (fr) Inhibiteurs de kinase de type polo
TN2009000138A1 (fr) Biaryl-ether-urees
MA32407B1 (fr) Sels et polymorphes d'un composé tétracycline
MA31597B1 (fr) Nouveaux herbicides
MA29311B1 (fr) Derives d'isoxazolines et son nouveau procede de production
ATE368031T1 (de) Neue gamma secretase inhibitoren
MA32903B1 (fr) Inhibiteurs de proteine-kinases
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA29870B1 (fr) Nouveaux dérivés de 1-azabicycloalkyles dans le traitement de troubles psychotiques et neurodégénératifs
MA31466B1 (fr) Derives de benzimidazole
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
SE0301368D0 (sv) Chemical compounds
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA27097A1 (fr) Aza-arylpiperazines
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
TN2010000173A1 (fr) Antagonistes de cgrp